Learn what PROTACs (Proteolysis-Targeting Chimeras) are, how they hijack the ubiquitin–proteasome system to degrade disease-driving proteins, and why these small molecule degraders are game-changers for targeting undruggable cancer proteins and overcoming drug resistance.
Discover how generative AI is transforming small molecule drug discovery by designing novel compounds in silico, optimizing potency and ADMET profiles, and enabling closed-loop discovery cycles across oncology, fibrosis, infectious disease, and CNS disorders.